Oxford BioMedica plc Interim Results for the Six Months Ended 30 June 2011
Click here to download the full 2011 interim results statement.Click here to download the 2011 interim results slide deck. Read More
Oxford BioMedica Announces Interim Data from Highest (5x) Dose Cohort in ProSavin® Phase I/II Study in Parkinson’s Disease
— Positive interim review of fourth patient cohort by Data Monitoring Committee — Oxford, UK – 4 August 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: Oxford Biomedica),… Read More
Oxford BioMedica Announces Ocular Programme Update
— RetinoStat® Progress in Phase I Study in Wet Age-Related Macular Degeneration Oxford, UK – 22 June 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: Oxford Biomedica), a leading… Read More
Oxford BioMedica Announces 5T4 Antibody Research Collaboration with ImaginAb
— ‘In vivo’ diagnostic rights granted for cancer imaging — Oxford, UK – 7 June 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the… Read More
Oxford BioMedica Plc Management and Board Changes
–Oxford BioMedica Appoints Alex Lewis as Director of Corporate Activities and Strategy– Oxford, UK – 24 May 2011: Oxford BioMedica (LSE: Oxford Biomedica),… Read More
Oxford BioMedica Announces Presentation Of New Clinical Data From ProSavin® Phase I/II Study in Parkinson’s Disease
— Six-month data from third cohort presented at ASGCT 14th Annual Meeting —— Highest efficacy results to date with 43% average motor function improvement —… Read More
Oxford BioMedica Interim Management Statement May 2011
Oxford, UK – 18 May 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: Oxford Biomedica), a leading gene therapy company, today publishes its interim management statement for the period from 1 January to 17 May 2011. Read More
Oxford BioMedica Broadens 5T4 Antibody Collaboration With Pfizer
— Diagnostic rights secured for Investigational New Drug application — Oxford, UK – 4 May 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the… Read More
Oxford BioMedica Announces Top-Line Results From Six Month Follow-Up of Third Patient Cohort in Prosavin® Phase I/II Study in Parkinson’s Disease
Oxford, UK – 3 May 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: Oxford Biomedica), a leading gene therapy company, announces that new data from the on-going Phase I/II trial of ProSavin® for the treatment of Parkinson’s disease (PD)… Read More
Oxford BioMedica Board Changes
Oxford, UK – 21 March 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: Oxford Biomedica), a leading gene therapy company, today announces that by mutual agreement, its Chairman, Dr Alan Kingsman, will leave the Board of… Read More
Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Stargardt Disease
— Second of four products in Phase I/II ocular programme partnered with sanofi-aventis approved to enter clinical development — Oxford, UK –… Read More
Oxford BioMedica Announces Publication of Trovax® Phase III Analyses in Cancer Immunology, Immunotherapy
— Immune Response Surrogate Algorithm Shown to be a Significant Predictor of Clinical Benefit — Oxford, UK – 15 March 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”)… Read More